UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November ~~October 23~~4, 2025

UTAH MEDICAL PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
UTAH	000-12575	87-0342734
Utah	000-12575	87-0342734
(State or other jurisdiction of	(Commission File Number)	(IRS Employer
incorporation or organization)		Identification No.)
7043 South 300 West
Midvale, Utah		84047
(Address of principal executive offices)		(Zip code)
Registrant’s telephone number, including area code:		Phone: (801) 566-1200
n/a
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

ITEM 25.02—~~RESULTS~~ DEPARTURE OF ~~OPERATIONS~~DIRECTORS ~~AND~~OR ~~FINANCIAL~~CERTAIN ~~CONDITION~~OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

~~Attached~~On ~~hereto~~October as31, ~~Exhibit~~2025, ~~99.1~~the ~~and~~Board ~~incorporated~~of byDirectors ~~reference~~of ~~herein is financial information for~~ Utah Medical Products, Inc. ~~for~~(UTMD) voted to increase the ~~three~~size ~~and~~of ~~nine~~the ~~months~~Board ~~ended~~of ~~September~~Directors ~~30,~~from ~~2025~~five to six members and ~~forward-looking~~to ~~statements~~appoint ~~relating~~Kevin Timken to ~~2025~~fill ~~and~~the ~~beyond~~vacancy ascreated ~~presented~~by the increase in athe ~~press~~number ~~release~~of ~~dated~~directors. ~~October~~Mr. ~~23,~~Timken ~~2025~~will serve on the Board’s Audit Committee and Compensation and Benefits Committee.

~~The~~Mr. ~~information~~Timken inwas ~~this~~Partner, ~~report~~Co-Leader ~~(including~~of ~~Exhibit~~Securities ~~99.1)~~and isCapital ~~being~~Markets ~~furnished~~at ~~pursuant~~Michael toBest ~~Item~~& ~~2.02~~Friedrich, LLP from 2017 to 2025, and ~~shall~~Partner, ~~not~~Kruse beLand ~~deemed~~Maycock to& beRicks, ~~“filed”~~LLC ~~for~~from ~~purposes~~2000 ofto ~~Section~~2017, 18during ofwhich ~~the~~25-year ~~Securities~~time ~~Exchange~~span ~~Act~~he ofadvised ~~1934,~~UTMD ason ~~amended,~~U.S. ~~(the~~Securities “and Exchange ~~Act”)~~Commission ormatters. Mr. ~~otherwise~~Timken ~~subject~~obtained toa J.D. degree from the ~~liabilities~~University of ~~that~~Utah ~~section,~~College ~~nor~~of ~~shall~~Law itin be1997, ~~deemed~~and toa beB.A. ~~incorporated~~cum bylaude ~~reference~~ in ~~any~~English ~~filing~~from ~~under~~ the ~~Securities~~University ~~Act~~ of ~~1933~~Northern orColorado ~~the~~in ~~Exchange Act~~1987.

As a member of the Board of directors, Mr. Timken received a grant of 10,000 stock options with an exercise price of $58.10 per share that will vest over a four-year period if he remains a member of the Board of Directors, and will receive the UTMD standard Board Member fee of $7,650 per quarter, which will be pro-rated for the final quarter of 2025.

ITEM 8.01—OTHER EVENTS

On November 4, 2025, Utah Medical Products, Inc. announced that it is increasing its regular quarterly cash dividend. A dividend of $.31 per share is payable on January 5, 2026 to shareholders of record at the close of business on December 16, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS

The following is filed as an exhibit to this report:

Exhibit Number*	Title of Document	Location
Item 99.1	~~Financial information for~~ Utah Medical Products, Inc. ~~for~~Appoints ~~the~~Director ~~three~~ and ~~nine~~Increases ~~months~~Quarterly ~~ended~~Cash ~~September 30, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated October 23, 2025.~~Dividend	This filing
		This filing

_______________________________________

*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	UTAH MEDICAL PRODUCTS, INC.
Dated: October 23, 2025	By:	/s/ Kevin L. Cornwell
Dated: November 4, 2025	By:	/s/ Kevin L. Cornwell
		Kevin L. Cornwell, Chief Executive Officer

Filing Compare · UTAH MEDICAL PRODUCTS INC